A New Era of Cancer Treatment

We are developing a robust clinical pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) products.

Our most advanced candidate, axicabtagene ciloleucel (formerly known as KTE-C19), has been submitted to the U.S. Food and Drug Administration for approval as a treatment for patients with relapsed or refractory aggressive non-Hodgkin lymphoma (NHL) who are ineligible for autologous stem cell transplant.  Additional indications are being pursued for the full KTE-C19 development program.

We are also advancing our first TCR product candidate, KITE-718, in a company-sponsored clinical trial.

Learn more about our ongoing clinical trials at www.clinicaltrials.gov.

Kite Pharma Expanded Access Policy

Treating physicians may request information about Expanded Access for a Kite Pharma therapy by contacting Kite Medical Information at 1-844-454-KITE.

Kite will evaluate these requests individually. Kite may provide physician requested Expanded Access for a Kite therapy for patients with no other available therapies and for patients who are not eligible to participate in a current Kite clinical trial. Kite will acknowledge receipt of the request via telephone call or email within 5 business days of receipt of the request.

Information on all Kite trials can be found on ClinicalTrials.gov.

Pursuant to the 21st Century Cures Act: the posting of policies by manufacturers and distributors shall not serve as a guarantee of access to any specific investigational therapy by any individual patient.